CLRB Stock — Cellectar Biosciences Inc

Cellectar Biosciences Inc (CLRB)

Updated October 16, 2026.

CLRB is a Stock. Its deepest 1-year drawdown was 76.0%.

Cellectar Biosciences is a clinical biopharmaceutical company developing drugs for cancer treatment, with its lead candidate CLR 131 (iopofosine I-131) undergoing Phase 2 studies for B-cell malignancies and other blood cancers, along with earlier-stage programs in radioconjugate therapy. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to clinical-stage biotech with no current income component, where returns depend entirely on clinical trial progress and potential commercialization success.

CLRB performance

Returns are updating. CLRB's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 76.0%.

CLRB key facts

Asset type

Stock

Asset class

Equity

Inception date

06/14/2005

Distribution frequency

None

Last close

$1.14 (as of 2026-10-16)

Market cap

$10,775,403

Average volume

338969.0

Payment date

07/17/2018

Beta

0.577

Payout ratio

0.0%

EPS

$-3.46

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CLRB risks and drawbacks

The deepest 1-year drawdown on record here is 76.0%.

Who may consider CLRB — and who may not

It is a weaker fit for investors who need monthly cash flow (CLRB does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CLRB

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions